Lunit vs Oatmeal Health (2026)
The AI Health Index reads this as a choice between an established detection company and a screening program building its own detection model. Lunit builds cancer detection across chest radiograph and mammography, with an evidence base in screening populations and regulatory footprints in several markets. Oatmeal runs lung cancer screening for federally qualified health centers and the imaging centers that scan their patients. Its LungIQ recovers smoking history from clinical notes to rank patients likely to be eligible, and its own nodule malignancy model, LungAI, is investigational and not FDA cleared, with a 510(k) pre submission filed in March 2026. Choose Lunit where detection with established regulatory footprints is the requirement. Choose Oatmeal where the gap is finding and navigating eligible patients in the safety net, and read LungAI as a product still in study. One thing a buyer should know: lung cancer screening carries a documented equity gap in eligibility and uptake, so ask any program for its screening and follow through rates by race and insurance status.
- Cancer detection across chest radiograph and mammography is the portfolio, from a KOSDAQ listed company with regulatory footprints in multiple markets.
- The evidence base sits in screening populations, the setting where both sensitivity and specificity bite.
- For a screening program, a vendor built around cancer detection is a closer fit than a general findings reader.
- Oatmeal targets lung cancer screening in federally qualified health centers, where uptake is lowest and the eligible population is largest relative to capacity. LungIQ recovers smoking history and risk factors from clinical notes with a language model and a classifier, because pack years are rarely in structured fields at these centers.
- Oatmeal publishes its business associate agreement as a click through on its site, readable before contracting. It binds subcontractors, requires breach reporting, and requires return or destruction of data at termination.
- Oatmeal states its regulatory position precisely: LungAI is investigational and not commercially available in the United States, a pivotal study at Mass General Brigham launches in the second quarter of 2026, and the billing code is marketed only for use after clearance.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Lunit and Oatmeal Health are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Lunit | Oatmeal Health |
|---|---|---|
| Primary category | Radiology & Imaging AI | Value Based Care Intelligence |
| Founded | 2013 | 2022 |
| Headquarters | Seoul, South Korea | San Jose, California, United States |
| Website | lunit.io | oatmealhealth.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Lunit is a cancer focused medical AI company founded in 2013, headquartered in Seoul and listed on KOSDAQ. Its radiology line is Lunit INSIGHT: MMG for 2D mammography (FDA cleared 2021), DBT for tomosynthesis (cleared 2023) and CXR for chest X-ray (CXR Triage cleared 2021).
Source: AI Health Index, August 2026
Oatmeal Health, founded in May 2022 by Jonathan Govette and based in San Jose, runs lung cancer screening programs for federally qualified health centers and the imaging centers and hospitals that scan their patients, serving Medicaid and Medicare populations that screening has historically reached least. LungIQ reads FQHC record exports, using a large language model and a classifier to recover smoking history and risk factors from clinical notes, and produces a ranked worklist of patients likely to meet the USPSTF screening criteria.
Source: AI Health Index, August 2026
Questions buyers ask
How are Lunit and Oatmeal Health priced and sold?
Lunit sells INSIGHT and its breast platform direct and through imaging equipment and viewer partners, so the software can arrive inside or alongside a scanner or viewer purchase.
With Oatmeal Health, the home, FQHC, imaging and business associate pages publish no price, unit of charge or contracting model for LungIQ or LungAI. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do Lunit and Oatmeal Health handle patient data?
In Lunit's case, the INSIGHT MMG FAQ says images from commercial sites are retained only for the duration of processing and are not used for retraining, that the models do not learn in real time, and that training data is biopsy proven material sourced through formal collaboration agreements.
For Oatmeal Health, the published agreement requires minimum necessary use, return or destruction of protected health information at termination, and de identification only under the HIPAA criteria, after which the data falls outside the agreement. It also permits data aggregation across the company's other covered entity customers. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
What evidence is published for Lunit and Oatmeal Health?
An independent external evaluation in JAMA Oncology (Salim and colleagues, 2020) compared three commercial algorithms on a retrospective Swedish screening cohort, and Lunit's had the highest accuracy.
In Oatmeal Health's case, the company itself states that prospective performance has not been established and that results may differ in clinical use. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How much do Lunit and Oatmeal Health leave to the clinician?
For Lunit, the product page says it supports single and double reading, and in Sweden's prospective ScreenTrustCAD study AI plus one radiologist was tested against two radiologists.
With Oatmeal Health, the company once described a language model chatbot explaining screening results and next steps to patients in their own language; the current site does not mention it, and if it is still offered, it is generative output about cancer screening delivered to patients with lower average health literacy and no published review, guardrails or escalation rule. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Neither vendor publishes a price. Oatmeal publishes the buyer's reimbursement routes instead, shared decision making visits under G0296 for health centers and CPT 0721T for imaging centers once LungAI is cleared, which is not the vendor's own price.
Oatmeal's performance figures, 0.96 area under the curve for both models, come from its own retrospective validation with no published report, and the language model that reads clinical notes is not named. It publishes no subgroup performance for either model, in a program built to reach the populations screening has reached least. Its business associate agreement permits data aggregation across its customers.
Lung cancer screening carries a documented equity gap in eligibility and uptake, so any program should report screening and follow through rates by race and insurance status rather than in aggregate. An intervention that lifts the average while widening the gap has not helped the people it was sold to reach.